The current stock price of ARMO is 49.98 null. In the past month the price increased by 0.16%.
ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.
ARMO BIOSCIENCES INC
575 Chesapeake Drive
Redwood City CA 94063
CEO: Peter Van Vlasselaer
Phone: 650-779-5075
ARMO Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing immunotherapies for the treatment of cancer, cardiovascular disease, fibrosis and inflammation. The Company's platform molecule AM0010 is a pegylated form of recombinant human IL-10, which has immune stimulating effects which induce the activation, proliferation and survival of intratumoral, tumor-reactive, cytotoxic CD8 T cells in cancer patients. Its product pipeline includes AM0001, an anti-PD-1 checkpoint inhibitor; AM0003 an anti-LAG-3 checkpoint inhibitor; AM0015 a form of recombinant human Interleukin-15 cytokine and AM0012 a form of recombinant human Interleukin-12 cytokine. ARMO Biosciences, Inc. is based in REDWOOD CITY, United States.
The current stock price of ARMO is 49.98 null. The price increased by 0.02% in the last trading session.
ARMO does not pay a dividend.
ARMO has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
ARMO stock is listed on the Nasdaq exchange.
ARMO BIOSCIENCES INC (ARMO) has a market capitalization of 1.52B null. This makes ARMO a Small Cap stock.
ChartMill assigns a technical rating of 6 / 10 to ARMO.
ChartMill assigns a fundamental rating of 3 / 10 to ARMO. ARMO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ARMO reported a non-GAAP Earnings per Share(EPS) of -28.52. The EPS decreased by -8.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.23% | ||
| ROE | -27.05% | ||
| Debt/Equity | 0 |